Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

136.05USD
5 Feb 2016
Change (% chg)

$-7.33 (-5.11%)
Prev Close
$143.38
Open
$142.66
Day's High
$143.13
Day's Low
$134.54
Volume
674,681
Avg. Vol
789,814
52-wk High
$242.37
52-wk Low
$130.00

ILMN.OQ

Chart for ILMN.OQ

About

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $19,917.72
Shares Outstanding(Mil.): 146.40
Dividend: --
Yield (%): --

Financials

  ILMN.OQ Industry Sector
P/E (TTM): 43.94 213.05 36.08
EPS (TTM): 3.10 -- --
ROI: 16.16 3.07 14.70
ROE: 27.88 3.39 15.64
Search Stocks

Illumina, partners make $100 million bet to detect cancer via blood test

CHICAGO Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease.

10 Jan 2016

UPDATE 1-Illumina, partners make $100 mln bet to detect cancer via blood test

CHICAGO, Jan 10 Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease.

10 Jan 2016

Illumina, partners make $100 million bet to detect cancer via blood test

CHICAGO Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease.

10 Jan 2016

Illumina, partners make $100 mln bet to detect cancer via blood test

CHICAGO, Jan 10 Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease.

10 Jan 2016

BRIEF-Biomerieux and Illumina launch Biomerieux EpiSeq

* Announced on Monday the launch of Biomerieux EpiSeq, an next-generation sequencing (NGS) service for epidemiological monitoring and control of healthcare-associated infections Source text for Eikon: Further company coverage:

15 Dec 2015

Circuit revives challenge to Illumina Down Syndrome test patent

A federal appeals court has revived a petition by Roche AG unit Ariosa Diagnostics seeking to invalidate a rival's patent on a noninvasive prenatal test for Down Syndrome.

16 Nov 2015

Biotechs extend selloff as pricing concerns intensify

NEW YORK U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure.

06 Oct 2015

BRIEF-Inno-Gene signs investment deal with International Technology Ventures

* Signs investment deal with US-based International Technology Ventures, LLC (ITV)

09 Sep 2015

Illumina partners with private equity firm on gene JV: sources

Gene-sequencing giant Illumina Inc, private equity firm Warburg Pincus LLC and venture capital firm Sutter Hill Ventures have agreed to invest $100 million to seed a new consumer-facing human genome platform called Helix, according to people familiar with the deal.

18 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks